vimarsana.com
Home
Live Updates
FDA OKs Vutrisiran for hATTR Amyloidosis With Polyneuropathy
FDA OKs Vutrisiran for hATTR Amyloidosis With Polyneuropathy
FDA OKs Vutrisiran for hATTR Amyloidosis With Polyneuropathy
Vutrisiran, an RNAi therapeutic given by subcutaneous injection once every 3 months, significantly improved signs and symptoms of hATTR polyneuropathy in a phase 3 study.
Related Keywords
Johns Hopkins University ,
Maryland ,
United States ,
Baltimore ,
Michael Polydefkis ,
Alnylam Pharmaceuticals ,
Drug Administration ,
Johns Hopkins University School Of Medicine ,
Ionis Pharmaceuticals ,
Alnylam Pharmaceuticals Inc ,
Medscape Medical News ,
Fast Track ,
Johns Hopkins University School ,
Alnylam Assist ,
Medscape Medical ,
Akcea Therapeutics ,
Amyloidosis ,
Transthyretin Related Amyloidosis ,
Drug Development ,
Us Food And Drug Administration ,
Nited States Food And Drug Administration ,
Fda ,
Neuropathy ,
Cardiomyopathy ,
Dyspnea ,
Arthralgia ,
Ainful Joint ,
Joint Pain ,
Disease Management ,